ClinicalTrials.gg
CompletedNCT06946160Updated May 7, 2025

A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines

A Phase 3 interventional study of Abobotulinumtoxin A (Espad Pharmed Darou Co.) and Abobotulinumtoxin A (Ipsen Co.) in Glabellar Lines and Glabellar Frown Lines, sponsored by Espad Pharmed. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-07.

Sponsored by Espad Pharmed · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled May 2024, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the efficacy and safety of AbobotulinumtoxinA (produced by Espad Pharmed Darou Co.) for correction of moderate to severe glabellar lines.

Hypothesis: AbobotulinumtoxinA (produced by Espad Pharmed Darou Co.) has acceptable efficacy and safety profile for correction of moderate to severe glabellar lines.

Primary Outcome: To verify the non-inferiority of the efficacy of AbobotulinumtoxinA (produced by Espad Pharmed Darou Co.) compared with AbobotulinumtoxinA (Dysport®, produced by Ipsen Co.) by percentage of responders at maximum frown at day 30 after treatment.

Researchers will compare the efficacy and safety profile of AbobotulinumtoxinA (produced by Espad Pharmed Darou Co.) with AbobotulinumtoxinA (Dysport®, produced by Ipsen Co.).

The study is designed as phase III, randomized, two armed, double-blind, parallel, active controlled, non-inferiority clinical trial.

Participants received a total dose of 40-60 units into 3 to 5 sites. After two weeks, a touch-up intervention could be done based on physician's assessment.

Read the detailed description

The study schedule includes Visit 0 (Screening), Visit 1 (Intervention, Day 0), and Follow-up Visits 2 (Day 14), 3 (Day 30), 4 (Day 90), and 5 (Day 120). At Visit 0, informed consent is obtained, and eligibility is assessed through initial evaluations and review of inclusion and exclusion criteria. At Visit 1, subjects are randomized (1:1) and receive the investigational treatment. Full-face photographs are obtained at Visit 1 (Before receiving the investigational treatment), and at Follow-up Visits 2, 3, 4, and 5, in both resting state and maximum frown. Efficacy is evaluated at Visits 3, 4, and 5. All adverse events are Recorded at all visits.

02

Conditions studied

  • Glabellar Lines
  • Glabellar Frown Lines

Keywords

  • glabellar lines
  • AbobotulinumtoxinA
03

In context

Lead sponsor

Espad Pharmed is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 to ≤65 years of age
  2. Willingness for signing and having signed the form
  3. Moderate to severe glabellar wrinkle at maximum frown based on glabellar lines severity scale (GLSS)
  4. be able to participate in the visit schedules and the study procedures.

Exclusion criteria

Exclusion Criteria:

  1. to botulinum toxin or any other component of the formulation, as well as to injectable fillers in the facial region.
  2. Previous treatment with botulinum toxin in facial areas within the past 6 months.
  3. Previous treatment with dermal fillers, dermabrasion, or photo rejuvenation in the glabellar region within the past 12 months.
  4. History of dermal filler injection in the forehead region within the past year.
  5. History of eyebrow tattooing or any other procedure involving the eyebrow area within the past month.
  6. Use of aminoglycosides, penicillamine, quinine, chloroquine, hydroxychloroquine, or calcium channel blockers within the past week.
  7. Use of anticoagulants or aspirin within the past 10 days (participants are not required to discontinue their anticoagulant therapy to be enrolled in the study).
  8. History of any cosmetic surgery (e.g., filler injections, chemical peels, or laser treatments) or use of products that induce skin remodeling or significantly affect the forehead area or its surroundings, including any aesthetic procedure involving the glabellar lines within the past 6 months.
  9. History of any surgical procedure involving facial muscles or scarring in the forehead or surrounding areas (including the eyebrows).
  10. Any planned aesthetic procedure involving the upper face during the course of the study.
  11. Presence of disorders that may affect neuromuscular function (e.g., myasthenia gravis, amyotrophic lateral sclerosis [ALS], or Eaton-Lambert syndrome).
  12. History of facial nerve paralysis.
  13. Presence of clearly visible and defined facial asymmetry.
  14. Ptosis of the eyelids or eyebrows due to facial muscle paralysis or a history thereof.
  15. Presence of any active infection or acute dermatological condition in the injection areas.
  16. Pregnancy (confirmed by urine test) or lactation.
  17. Participation in other clinical studies within 30 days prior to randomization or intention to participate in other clinical trials.
  18. Any other condition or circumstance that may pose a risk to the participant or interfere with the satisfactory completion of the clinical outcome.
  19. History of participation in other clinical trials involving botulinum neurotoxin products or fillers within the past 6 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    Abobotulinumtoxin A (produced by Espad Pharmed Darou Co.)

    Vial of AbobotulinumtoxinA (produced by Espad Pharmed Darou Co.), administered via deep intramuscular injection into 3 to 5 sites in the glabellar area using a 1 ml syringe, with a total dose of 40 to 60 International Units (IU), administered in a single treatment session.

    Drug: Abobotulinumtoxin A (Espad Pharmed Darou Co.)

  • Active comparator
    Abobotulinumtoxin A (Dysport®, produced by Ipsen Co.)

    Vial of AbobotulinumtoxinA (Dysport®, produced by Ipsen Co.), administered via deep intramuscular injection into 3 to 5 sites in the glabellar area using a 1 ml syringe, with a total dose of 40 to 60 International Units (IU), administered in a single treatment session.

    Drug: Abobotulinumtoxin A (Ipsen Co.)

Interventions

  • DrugAbobotulinumtoxin A (Espad Pharmed Darou Co.)

    Drug pages: abobotulinumtoxinA · Botulinum toxin type A

    Vial of Abobotulinumtoxin A (produced by Espad Pharmed Darou Co.), administered via deep intramuscular injection

  • DrugAbobotulinumtoxin A (Ipsen Co.)

    Drug pages: abobotulinumtoxinA · Botulinum toxin type A

    Vial of AbobotulinumtoxinA (Dysport®, produced by Ipsen Co.), administered via deep intramuscular injection

06

What researchers measure

Primary outcomes

  1. Responders at maximum frown by investigator's assessment

    Percentage of responders measured by the investigator's live assessment based on Glabellar Line Severity Scale (GLSS) at maximum frown at day 30 after treatment The Glabellar Line Severity Scale (GLSS) is a 4-grade scale defined as follows: 0 = no glabellar lines, 1 = mild lines, 2 = moderate lines, 3 = severe lines. Higher scores indicate more severe glabellar lines. Participants were considered responders if they showed a reduction of at least 2 points from baseline on the scale.

    Time frame: Day 30

Secondary outcomes

  1. Responders at rest by investigator's assessment

    Percentage of responders measured by the investigator's live assessment based on Glabellar Line Severity Scale (GLSS) at rest at days 30, 90 and 120 after treatment The Glabellar Line Severity Scale (GLSS) is a 4-grade scale defined as follows: 0 = no glabellar lines, 1 = mild lines, 2 = moderate lines, 3 = severe lines. Higher scores indicate more severe glabellar lines. Participants were considered responders if they showed a reduction of at least 2 points from baseline on the scale.

    Time frame: Days 30, 90 and 120

  2. Responders at maximum frown by subject's self-assessment

    Percentage of responders measured by the subject's self-assessment (SSA) at maximum frown at days 30, 90 and 120 after treatment The 4-grade subject's self-assessment scale defined as follows: 0 = no glabellar lines, 1 = mild lines, 2 = moderate lines, 3 = severe lines. Higher scores indicate more severe glabellar lines. Responders are defined as those reporting a reduction of at least 2 points from baseline.

    Time frame: days 30, 90 and 120

  3. Responders at rest by subject's self-assessment

    Percentage of responders measured by the subject's self-assessment (SSA) at rest at days 30, 90 and 120 after treatment The 4-grade subject's self-assessment scale defined as follows: 0 = no glabellar lines, 1 = mild lines, 2 = moderate lines, 3 = severe lines. Higher scores indicate more severe glabellar lines. Responders are defined as those reporting a reduction of at least 2 points from baseline.

    Time frame: days 30, 90 and 120

  4. Responders at maximum frown by investigator's assessment

    Percentage of responders measured by the investigator's live assessment based on Glabellar Line Severity Scale (GLSS) at maximum frown at days 90 and 120 after treatment The Glabellar Line Severity Scale (GLSS) is a 4-grade scale defined as follows: 0 = no glabellar lines, 1 = mild lines, 2 = moderate lines, 3 = severe lines. Higher scores indicate more severe glabellar lines. Participants were considered responders if they showed a reduction of at least 2 points from baseline on the scale.

    Time frame: days 90 and 120

  5. Total injected dose (visit 1 and touch-up visit)

    Time frame: Day 14

  6. Onset of action measured by the subject's self-assessment (SSA) at rest

    The participants were asked to record the date on which they first noticed the onset of the product's efficacy and to inform the investigator of this date during the visit on day 14.

    Time frame: Day 14

  7. Onset of action measured by the subject's self-assessment (SSA) at maximum frown

    The participants were asked to record the date on which they first noticed the onset of the product's efficacy and to inform the investigator of this date during the visit on day 14.

    Time frame: Day 14

  8. Safety assessment by evaluation of adverse events (AEs)

    Adverse events (AEs) were assessed at all visits. All reported events were classified as mild, moderate, or severe. Moreover, seriousness of Adverse events was assessed according to International Council for Harmonization (ICH-E2B) guidelines. The causality relation was assessed based on the World Health Organization (WHO) criteria.

    Time frame: Visit 0 (screening), visit 1 (Day 0), visit 2 (Day 14), visit 3 (Day 30), visit 4 (Day 90), visit 5 (Day 120)

07

Study locations

1 site
  • Center for Research and Training in Skin Diseases And Leprosy
    Tehran, Iran, Islamic Republic of
08

References and documents

Individual participant data

Plan to share: No — Data produced in the present study are available upon reasonable request from the investigators.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Feb 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2025
First posted
Apr 27, 2025
StartActual
May 28, 2024
Primary completionActual
Feb 18, 2025
CompletionActual
Feb 18, 2025
Last update
May 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06946160
Lead sponsor
Espad Pharmed
Responsible party
Sponsor
First posted
Apr 27, 2025
Start date
May 28, 2024
Primary completion
Feb 18, 2025
Completion
Feb 18, 2025
Last update
May 7, 2025

Study contacts

Alireza Firooz, Medical Doctor
principal investigator · Center for Research and Training in Skin Diseases and Leprosy, Tehran, Tehran 1416613675

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: abobotulinumtoxinA · Botulinum toxin type A

Start the discussion